The Department of Justice's decision to no longer defend critical provisions of the Affordable Care Act (ACA) risks health insurance coverage for people with cystic fibrosis and other pre-existing conditions.
Site Search
As part of the Cystic Fibrosis Foundation's 11th annual March on the Hill, more than 100 advocates from 44 states met with nearly 300 elected officials or their staff to help ensure that everyone with cystic fibrosis has access to high-quality, specialized care and adequate, affordable health care.
Ten patient and provider groups, representing millions of Americans, issued the following statement in response to the release of the nonpartisan Congressional Budget Office's (CBO) scores of two pieces of health care reform legislation currently being considered by the U.S. Senate.
Bipartisan legislation could help patients access necessary prescription drugs by potentially reducing the financial burden that results from complex and hard-to-navigate health insurance plans
206 care center directors sign a letter citing clinical consequences if decision moves forward.
My service dog, Jasper, and I relocated across the country and began to find our footing in our new home just before devastating forest fires started spreading around the area. Now, I feel more grateful than ever for the irreplaceable things in life, like Jasper.
Although adults with cystic fibrosis are at a significantly higher risk of developing colorectal cancer than the general population, colonoscopy screening is an effective way to prevent and treat colorectal cancer by helping to detect and remove polyps. People with CF should be screened starting at age 40 (or 30 for those who have had a transplant). Find out how early screening can help reduce the risk.
During the annual event, volunteers advocated for the PASTEUR Act and the HELP Copays Act, two bipartisan pieces of legislation that could have substantial, positive impact on the CF community.
Cost effectiveness analysis must be used carefully and as part of a comprehensive evaluation of the value a treatment, such as highly effective modulators, provide to people living with cystic fibrosis.